Tempus AI

Tempus AI Accounts Payable

The Accounts Payable of Tempus AI (TEM) as of Nov 20, 2026 is 81.99 M USD. In the previous year, Accounts Payable was 53.80 M USD — a change of 52.39% (higher).

Accounts Payable

81.99 MUSD

YoY

52.39%

Last updated:

Accounts Payable of Tempus AI is 2025 81.99 M USD. Accounts Payable of Tempus AI was 2024 53.80 M USD. It decreases by 52.39% higher compared to the previous year.

The Tempus AI Accounts Payable history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Accounts Payable
Date
Accounts Payable
Jan 1, 2019
13.42 M USD
Jan 1, 2020
53.57 M USD
Jan 1, 2021
33.75 M USD
Jan 1, 2022
45.99 M USD
Jan 1, 2023
54.42 M USD
Jan 1, 2024
53.80 M USD
Jan 1, 2025
81.99 M USD
The Tempus AI Accounts Payable history
YEARAccounts PayableYoY
81.99 MUSD+52.39%
53.80 MUSD-1.13%
54.42 MUSD+18.34%
45.99 MUSD+36.25%
33.75 MUSD-36.99%
53.57 MUSD+299.34%
13.42 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tempus AI Stock analysis

What does Tempus AI do? Tempus AI Inc provides next generation diagnostics through genomics, data, and AI applications. Its genomics product line includes next generation sequencing, diagnostics, PCR, profiling, molecular genotyping, and pathology testing. The AI applications focus on algorithmic diagnostics, software as a medical device, and clinical decision support tools. The primary AI product Next uses machine learning to identify care gaps for oncology and cardiology patients. The company serves healthcare providers and life sciences organizations seeking personalized medicine solutions. Tempus AI Inc's revenue comes from its genomics and AI product lines. The genomics services are delivered through its laboratories, offering sequencing, diagnostics, and molecular testing. The AI applications, particularly Next, are sold as software solutions to healthcare institutions. The target customers are healthcare providers and life sciences companies that require advanced diagnostic tools for personalized treatment plans. The company operates in the Life Sciences Tools & Services industry, focusing on oncology and cardiology segments. The company's genomics product line generates revenue through laboratory services for molecular pathology testing. AI applications like Next are sold as medical device software, targeting healthcare institutions for clinical decision support. The primary segments served are oncology and cardiology, where personalized medicine is critical. The company's products are designed to integrate with existing healthcare data systems to improve patient care outcomes. Tempus AI is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tempus AI stock

Accounts Payable of Tempus AI is 81.99 M USD in 2025.

Accounts Payable of Tempus AI changed from 53.80 M USD to 81.99 M USD, representing a 52.39% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Payable Tempus AI since 2006 – with annual values, charts, and detailed analysis.

Accounts payable represents money owed to suppliers for goods and services received. It is a key component of working capital management.

Accounts Payable's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Payable's Tempus AI historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Tempus AI

All Key Metrics — Tempus AI